Market Overview

UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources

Share:
Related CORT
Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy
Mid-Day Market Update: Conatus Jumps Following Announcement of Licensing Deal With Novartis; Sucampo Shares Slide

In a report published Monday, Stifel analyst Annabel Samimy terminated coverage on Corcept Therapeutics (NASDAQ: CORT).

In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Corcept Therapeutics. Our last rating was Hold. Our last net loss estimates were ($0.53) for FY 2014, ($0.38) for 2015, breakeven for FY2016, $0.40 for FY2017, and $1.12 for FY 2018. However, these estimates should not be used as an indicator for the company going forward.”

Corcept Therapeutics closed on Friday at $4.08.

Latest Ratings for CORT

DateFirmActionFromTo
Feb 2017Ladenburg ThalmannInitiates Coverage OnBuy
Dec 2015Janney CapitalInitiates Coverage onBuy
Apr 2015FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for CORT
View the Latest Analyst Ratings

Posted-In: Annabel Samimy StifelAnalyst Color Termination Analyst Ratings

 

Related Articles (CORT)

View Comments and Join the Discussion!